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I
n patients with pulmonary hypertension (PH), restricted blood flow through the pulmonary arterial circulation due to increased pulmonary vascular resistance often results in right-sided heart failure. Despite recent advances in the treatment of PH, the 5-year mortality rate for individuals with this disease still approaches 50%, which highlights an urgent need for novel therapeutics. 1 Current standards of care for patients with PH typically involve the use of vasoactive drugs, including endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, and prostacyclins. More effective therapeutic strategies will likely be based on the combined use of vasodilators and agents that target distinct pathogenic mechanisms in PH, such as pulmonary vascular inflammation and fibrosis, as well as aberrant proliferation of smooth muscle cells, endothelial cells, and fibroblasts in the lung vasculature. 2 Additionally, because right ventricular (RV) failure is the cause of death in the majority of PH patients, 3, 4 and it is unclear whether standards of care for left ventricular (LV) dysfunction (eg, ␤-blockers and angiotensin-converting enzyme inhibitors) are effective for RV failure, 5 increased emphasis needs to be placed on elucidating pathogenic mechanisms in this chamber of the heart. Given the multitude of cell types and signaling cascades that govern pulmonary vascular and associated RV remodeling, it is predicted that effective therapeutic strategies for PH will involve targeting distal signaling mediators. Histone deacetylases (HDACs) may represent such targets.
HDACs control cell proliferation, inflammation, and fibrosis by catalyzing removal of acetyl groups from lysine residues in a variety of proteins. The 18 mammalian HDACs are encoded by distinct genes and are grouped into 4 classes. 6 Two broad-spectrum HDAC inhibitors are approved for the treatment of cancer. One of these compounds, SAHA (suberoylanilide hydroxamic acid), and other "pan"-HDAC inhibitors have been shown to be efficacious in animal models of LV dysfunction, which suggests unforeseen potential for HDAC inhibitors for the treatment of heart failure. 7 However, a recent report of findings in a model of pulmonary artery (PA) banding suggested that pan-HDAC inhibitors have Figure 1 . Class I HDAC inhibition in a hypoxia model of pulmonary hypertension. A, Rats were housed in hypobaric chambers and received intraperitoneal injection of the class I HDAC inhibitor MGCD0103 (10 mg/kg) every other day for 3 weeks. On days when compound was not delivered, animals were treated with vehicle control. Normoxic and hypoxic control rats were dosed with compound vehicle on a daily basis. B, Rats were weighed daily. C and D, Class I and class IIa HDAC enzymatic activity was quantified in lung and RV homogenates. E, Lung homogenates were immunoblotted for acetyl-␣-tubulin and total ␣-tubulin. Lung lysates from an independent study with the pan-HDAC inhibitor SAHA were used as controls. Pb indicates barometric pressure.
deleterious effects on the RV, 8 which casts doubt on the utility of this class of compounds for patients with right-sided heart failure caused by diseases such as PH.
Here, we tested the hypothesis that selective inhibition of a subset of HDACs will provide a safe and effective means of treating PH and RV remodeling. MGCD0103, a smallmolecule HDAC inhibitor that is in clinical development for cancer and is highly selective for class I HDACs 1, 2, and 3, was tested for efficacy in a rat model of PH induced by chronic hypoxia. Rationale for using this compound was based on prior studies that implicated class I HDACs in the control of LV remodeling, 9 -12 and on the well-described role for this HDAC class in the control of aberrant cell proliferation, 13 such as is found in lung vasculature of patients with PH. 14 The data demonstrate that class I HDAC inhibition significantly reduces pulmonary arterial pressure (PAP) through a mechanism that involves suppression of pulmonary vascular smooth muscle cell proliferation, while maintaining RV function and blocking cellular and molecular processes that contribute to RV failure. Another class I HDAC inhibitor that is in clinical development, MS-275, also effectively reduced hypoxia-induced PH. These results highlight the potential of isoform-selective HDAC inhibitors for the treatment of cardiovascular diseases.
Methods

Experimental Animals
All animal experiments were conducted in accordance with the National Institutes of Health's "Guide for the Care and Use of Laboratory Animals" and were approved by the Institutional Animal Care and Use Committee at the University of Colorado Denver. Ten-week-old male Sprague-Dawley (SD) rats weighing 250 to 280 g (Charles River Laboratories) were used for all studies. MGCD0103 and MS-275 (Selleck Chemicals, Boston, MA) were delivered every other day via daily intraperitoneal injection at concentrations of 10 and 3 mg/kg, respectively, in a 50:50 DMSO:PEG-300 vehicle. Tadalafil (Sequoia Research Products, Reading, United Kingdom; 10 mg/kg) was dosed daily by oral gavage in a 20% Cremophor/H 2 O vehicle (dose volume 2 mL/kg). MGCD0103, MS-275, and tadalafil administration began the day animals were placed in chambers. Normoxic and hypoxic control animals were dosed on the same schedule with compound vehicles. Animals were killed 20 hours after compound dosing, unless otherwise indicated.
Hemodynamic Analysis
Echocardiographic analyses were performed with a Vevo770 (VisualSonics, Toronto, Ontario, Canada). Pulse-wave Doppler of pulmonary outflow was recorded in the parasternal short-axis view at the level of the aortic valve. Baseline measurements were obtained 1 day before animals were placed in chambers. PAP was measured with a Millar catheter placed in the main PA via the RV; correct placement of the catheter was confirmed by observing a significant rise in diastolic pressure as the catheter moved out of the ventricle. Systemic blood pressure was monitored with another pressure catheter inserted in the femoral artery. Cardiac performance was assessed with a pressure-volume system (Scisense Inc, London, Ontario, Canada). For analyses, animals were anesthetized with 2% isoflurane, and their body temperature was maintained at 37°C. Hemodynamic analyses were performed Ϸ20 to 24 hours after the final dose of compound (MGCD0103 and MS-275) or 2 hours after dosing (tadalafil). Total pulmonary vascular resistance index was calculated as mean PAP/cardiac index, where cardiac index equals cardiac output divided by body weight, as described previously. 15 For data from all in vivo studies, GraphPad Prism software (GraphPad Software, Inc, La Jolla, CA) was used to generate graphs and analyze data. ANOVA with Bonferroni post test (PϽ0.05) was used to determine statistical differences between groups. Rats presented no health concerns associated with compound treatment. Animals were monitored daily and showed no evidence of paleness in eyes, nose, or skin, which are the most common signs of hematologic toxicities. Rats were alert and conducted normal activities such as eating, drinking, and grooming.
Results
To assess the role of class I HDACs in PH and RV remodeling, adult Sprague-Dawley rats were housed in a hypobaric chamber to simulate an altitude of 18 000 feet above sea level and create a hypoxic environment (10% O 2 ). Normoxic control rats were maintained in chambers that simulated sea level (21% O 2 ). Animals were treated with compound vehicle or MGCD0103, 16 a selective inhibitor of class I HDACs that is currently in clinical trials for the treatment of cancer ( Figure 1A ). Normoxic and hypoxic control rats were dosed with compound vehicle alone. Rats receiving MGCD0103 gained weight at a rate similar to vehicle controls, which indicates that the compound was well tolerated ( Figure 1B ). Enzymatic assays with lung and RV homogenates confirmed that MGCD0103 selectively inhibited class I but not class IIa HDACs ( Figures 1C and 1D ). MGCD0103 did not increase tubulin acetylation in lung ( Figure 1E ) or heart (not shown), which indicates that the compound did not inhibit the tubulin deacetylase, HDAC6.
Three weeks of hypoxia resulted in an Ϸ2-fold increase in PA systolic pressure, as determined by placement of a Millar catheter into the PA (Figure 2A ). MGCD0103 significantly reduced PA systolic pressure and PA pulse pressure, which suggests that the compound increased arterial compliance in the lungs of hypoxic rats (Figures 2A and 2B ). Mean PAP values correlated with PA systolic pressure and PA pulse pressure ( Figure 2C ). Systemic blood pressure was unaffected by MGCD0103 (Online Table II) , and MGCD0103 had no impact on pulmonary pressures in normoxic rats (Online Figures IA-1C ). The class I HDAC inhibitor reduced PAP more effectively than tadalafil, a phosphodiesterase type 5 inhibitor used to treat patients with PH ( Figure 2D) .
A follow-up study assessed effects of MGCD0103 on RV function and pulmonary blood flow in hypoxic rats. Importantly, cardiac output was maintained in animals that received the class I HDAC inhibitor ( Figure 3A) , which rules out the possibility that the observed reduction in PAP was a consequence of compound-mediated impairment of cardiac function. Consistent with the findings shown in Figure 2 , MGCD0103 also significantly reduced pulmonary vascular resistance in hypoxic rats ( Figure 3B ). Pressure-volume analyses confirmed that MGCD0103 did not negatively impact RV function (Table) . In line with the PAP measurements, Doppler echocardiography revealed reduced PA acceleration time and velocity time integral in hypoxic rats, which was rescued by MGCD0103 ( Figures 3C and 3D ). Reduced pulmonary vascular compliance often causes transient cessation of forward PA blood flow during systole, which is detected by Doppler as a "notch" in the signal. 17 Systolic notching was readily detected in hypoxic control rats but not in animals treated with MGCD0103 ( Figure 3E) .
Biochemical, morphological, and histological analyses were performed to further address the action of MGCD0103 in the RV. Consistent with a role for class I HDACs in RV remodeling, HDAC1, HDAC2, and HDAC3 protein levels were elevated in RVs from hypoxic rats and normalized by MGCD0103 treatment (Figures 4A and 4B) . Surprisingly, class I HDAC inhibition only modestly reduced RV hypertrophy ( Figure 4C ; Online Table III) ; however, RV expression of genes associated with pathological hypertrophy, including brain natriuretic peptide and ␣-skeletal actin, was reduced by MGCD0103 ( Figure 4D ). Tadalafil also reduced RV hypertrophy (supplemental Figures 2A-2C) . In normoxic rats, MGCD0103 did not affect expression of class I HDACs in the RV and did not reduce RV mass or expression of brain natriuretic peptide or ␣-skeletal actin (supplemental Figures  3A-3D) .
In contrast to the increase in RV cell death observed in animals treated with a pan-HDAC inhibitor, 8 selective inhibition of class I HDACs with MGCD0103 blocked induction of proapoptotic caspase activity in RVs of hypoxic rats ( Figures 4E and 4F) . Given the role of inflammation in RV remodeling 14 and the anti-inflammatory actions of HDAC inhibitors, 18 a cytokine/chemokine protein array was performed with RV homogenates from rats treated with vehicle or MGCD0103. MGCD0103 blunted hypoxia-mediated induction of interleukin-1␤, interleukin-2, and cytokine-induced neutrophil chemoattractant-2 protein levels in the RV (Figure 4G ), which suggests that class I HDAC inhibition blocked activation/recruitment of macrophages, T lymphocytes, and neutrophils. Results from the entire array are shown in the Data Supplement (supplemental Figure 4) .
As shown in Figure 5 , an independent class I HDAC inhibitor, MS-275, also effectively blunted hypoxia-induced PH. MS-275 also reduced hypoxia-mediated RV hypertrophy ( Figure 5C ; Online Table III) . Like MGCD0103, MS-275 has a benzamide warhead that confers selectivity for class I HDACs 19 ; however, linker and surface recognition domains in MS-275 are distinct from those of MGCD0103. Given that these compounds have distinct chemical structures, the results suggest that the reduction in PAP mediated by MGCD0103 and MS-275 is due to selective inhibition of class I HDACs rather than an off-target effect.
To begin to address the mechanism by which class I HDAC inhibition reduces PAP in the setting of hypoxia, experiments were performed to determine whether MGCD0103 exerts acute vasodilator effects. Pulmonary artery strips (1.5 mmϫ200 m) were isolated from adult Sprague-Dawley rats, attached to a force transducer, and stimulated to contract with potassium. Acute treatment with MGCD0103 failed to augment potassium-mediated contraction of PAs under these conditions, whereas sodium nitroprusside (1 mol/L), which directly activates guanylate cyclase, effectively relaxed the contraction ( Figure 6A ). Consistent with these findings, acute administration of MGCD0103 (2 or 20 hours) in treatment-naïve hypoxic rats did not lower PAP ( Figure 6B ).
Medial thickening caused by abnormal proliferation of PA smooth muscle cells contributes to the pathogenesis of PH. 20 Given the essential role for class I HDACs in the control of cell proliferation, 13 analyses were performed to determine whether efficacy of MGCD0103 in the PH model was linked to reduced pulmonary vascular remodeling. Hypoxiamediated medial thickening of vessels in the lung was inhibited by MGCD0103 ( Figure 7A, upper panel) , which was associated with reduced numbers of proliferating cells (presumably smooth muscle cells) in this vessel compartment ( Figure 7A, lower panel) . Quantification of PA medial thickness revealed complete normalization in MGCD0103-treated rats ( Figure 7C) ; MGCD0103 had no effect on medial thickness of pulmonary vessels from normoxic rats (supplemental Figure 5A ). In contrast to MGCD0103, tadalafil failed to significantly reduce hypoxia-dependent medial thickening of PAs (supplemental Figure 5B) .
Studies with MGCD0103 and cultured cells confirmed that the class I HDAC inhibitor directly suppressed PA smooth muscle cell proliferation through a mechanism that involved induction of genes that promote cell cycle arrest, including FoxO3a and p27 ( Figures 7C through 7E ). MGCD0103 also reduced FoxO3a phosphorylation at threonine 32 in PA smooth muscle cells cultured under hypoxic conditions (Figure 7D, lane 4) ; phosphorylation of this site promotes nuclear export of FoxO3a, which results in activation of genes that promote cell proliferation. 21, 22 Taken together, the data suggest that class I HDAC inhibition improves pulmonary hemodynamics through an antiproliferative mechanism.
Discussion
Here, we demonstrate in vivo efficacy of selective class I HDAC inhibitors in a preclinical model of PH. Two class I HDAC inhibitors, MGCD0103 and MS-275, reduced hypoxiamediated PH in rats in a manner that correlated with suppression of medial thickening of PAs and inhibition of smooth muscle cell proliferation in these vessels. Reduced PA smooth muscle cell proliferation through class I HDAC inhibition was caused in part by upregulation of the antiproliferative transcription factor FoxO3a. Importantly, we also demonstrated that RV function was maintained in the face of class I HDAC inhibition and that indices of adverse ventricular remodeling (eg, myocyte apoptosis and inflammation) were blunted by selective inhibition of class I HDACs. This is in contrast to what was observed previously with the pan-HDAC inhibitor trichostatin A and supports the hypothesis that isoform-selective HDAC inhibition will be safer than general HDAC inhibition in the setting of RV pressure overload. Both MGCD0103 (Mocetinostat) and MS-275 (Entinostat) are in clinical development for cancer and are well tolerated by humans, thus highlighting the translational potential of the present findings. PH is associated with dramatic structural remodeling of the pulmonary vasculature. Remodeling of PAs is due in part to abnormal proliferation of PA smooth muscle cells, resulting muscularization and stenosis of the vessels, and thereby increasing pulmonary vascular resistance. 20 The remodeling process is exacerbated by aberrant proliferation of other cell types, including endothelial cells and fibroblasts, as well as vascular inflammation and adventitial fibrosis. 23 As such, it has been proposed that antiproliferative agents should be used in combination with vasodilators for the treatment of PH, and recent clinical trials with anticancer agents such as the tyrosine kinase inhibitor imatinib are addressing this hypothesis. 24 HDAC inhibitors are in use for the treatment of cancer on the basis of their ability to block proliferation and stimulate apoptosis of transformed cells. 25 Class I HDACs 1, 2, and 3, which reside in the nucleus and regulate epigenetic processes through deacetylation of nucleosomal histones, appear to be the HDAC isoforms that are primarily responsible for cell cycle control. 13 In addition to their anticancer actions, clinical and preclinical studies have revealed that HDAC inhibitors potently suppress inflammation, fibrosis, and restenosis and have beneficial effects on the LV in the setting of increased afterload. 7 Furthermore, we found class I HDAC inhibition blocks the persistent, proinflammatory phenotype of pulmonary adventitial fibroblasts derived of hypoxic calves. 26 Given these findings, HDAC inhibitors appear to be ideally suited for the treatment of PH, and the results with MGCD0103 and MS-275 described here support this notion. . MGCD0103 is not an acute vasodilator. A, Rat PA strips (1.5 mmϫ200 m) were hung on a "bubble plate" between 2 tungsten wires. One wire was fixed and the other attached to a force transducer. Intact strips were stimulated with high potassium (KES). MGCD0103 had no effect on the potassium-mediated contraction at any concentration (10 -300 nmol/L); however, when strips were washed with normal extracellular solution (NES) and contracted again with potassium, sodium nitroprusside (SNP, 1 mol/L) effectively relaxed the vessel. B, Rats were maintained in hypobaric chambers for 3 weeks. On the final day of the study, animals received a single injection of MGDC0103 (10 mg/kg) 2 or 20 hours before PAP was measured. Acute administration of MGCD0103 failed to lower hypoxia-induced increases in PA systolic pressure (PASP) or PA pulse pressure (PAPP).
Two reports have addressed effects of HDAC inhibitors in models of RV remodeling. Valproic acid was shown to block RV cardiac hypertrophy in response to PA banding, as well as in the setting of PH caused by monocrotaline-induced lung injury. 27 In contrast, trichostatin A failed to block hypertrophy in response to PA banding and actually appeared to worsen RV function. 8 Valproic acid is a weak HDAC inhibitor that has many additional pharmacological activities, including regulation of ion channels, glycogen synthase kinase-3␤, and mitogen-activated protein kinases. 28 Thus, it is unclear whether the beneficial effects of this compound on the RV were a direct consequence of HDAC inhibition. Trichostatin A is a potent pan-HDAC inhibitor. 19 The deleterious effects of this compound on the RV (eg, decreased cardiac output, increased RV dilatation, and apoptosis) could be a reflection of a protective role for HDAC(s) in this chamber of the heart. It is interesting to note that valproic acid, which exhibits selectivity for class I HDACs, did not cause adverse effects in the PA banding model. 8 The present findings suggest that with regard to the RV, isoform-selective HDAC inhibition is safer than nonselective suppression of HDAC activity. This is evidenced by the ability of MGCD0103 to block RV apoptosis and inflammation and maintain RV contractile function in chronically hypoxic rats (Figure 4 ; Table) . Nonetheless, the model used for our studies (3 weeks of hypoxia in Sprague-Dawley rats) is mild with regard to RV remodeling (Table) and represents a model of PH caused by interstitial lung disease and/or hypoxemia (World Health Organization group III PH). It will be important to extend the current findings to more severe models of PH and RV dysfunction, such as the SUGEN plus hypoxia model, 29, 30 to determine whether the beneficial effects of class I HDAC inhibitors are generalizable to other forms of PH, including World Health Organization group I idiopathic pulmonary arterial hypertension.
The modest effect of MGCD0103 on RV hypertrophy is surprising given the prior demonstrations of antihypertrophic activity of HDAC inhibitors in models of LV dysfunction 9 but is consistent with the inability of trichostatin A to block hypertrophy in response to PA banding. 8 These results may reflect differential requirements for HDACs in the control of hypertrophy in the LV and RV and, more broadly, differences in signaling and transcriptional mechanisms that control growth of the 2 chambers. Interestingly, tadalafil reduced RV hypertrophy as efficiently as MGCD0103 despite having a more modest effect on PAP than the class I HDAC inhibitor. This finding may point to a direct role for phosphodiesterase type 5 in the regulation of RV growth in response to chronic hypoxia.
The data presented here suggest that class I HDACs function in multiple cell types in lungs and RV as key components of pathogenic pathways that trigger increases in pulmonary vascular resistance and culminate in right-sided heart failure. Robust efforts in industry are focused on clinical development of isoform-selective HDAC inhibitors for oncology and nononcology indications. The present results validate a role for class I HDACs in the pathogenesis of PH and justify expanded preclinical and clinical evaluation of class I HDAC inhibitors to determine the utility of this compound class for patients with PH and RV failure.
HDAC inhibitors are efficacious in models of left ventricular failure, blocking cardiac hypertrophy and fibrosis and improving systolic and diastolic performance of the ventricle. These results have suggested unforeseen potential for this class of compounds for the treatment of heart failure. However, in a recent study, a pan-HDAC inhibitor was shown to negatively impact the RV in the setting of pressure overload. The present study was performed to address the hypothesis that selective inhibition of a subset of HDACs, rather than all HDACs, will provide a safe and efficacious means of treating PH and associated RV remodeling. In addition, because the pathogenesis of PH involves increased proliferation of cells in the pulmonary vasculature, we reasoned that the antiproliferative action of HDAC inhibitors would suppress PH. We show for the first time that small molecules that selectively block class I HDACs (HDACs 1, 2, and 3) reduce hypoxia-induced PH in a manner that correlates with blunted medial thickening of pulmonary arterials and reduce proliferation of smooth muscle cells in these vessels. Importantly, class I HDAC inhibition was well tolerated by the RV and was associated with blockade of cellular events (eg, myocyte apoptosis and inflammation) that contribute to adverse RV remodeling. These findings justify expanded evaluation of class I HDAC inhibitors to determine the utility of this compound class for patients with PH and RV failure.
